Reproducibility2020 is a challenge and action plan for the bio-medical research community to significantly improve the quality of pre-clinical biological research by year 2020.

Reproducibility has emerged as a major concern that contributes to delays and increased costs of discovery and development of treatments and cures. The bio-medical research community has begun to coalesce around practical and actionable solutions. Through Reproducibility2020, launched in February 2016, GBSI will devote its resources to affect change where its programs can make the greatest difference, work with partners to advance the broader agenda to improve the quality of scientific discovery in pre-clinical biological research settings, and keep stakeholders informed about movement and progress.

The $28 Billion Problem

Irreproducible pre-clinical research is a global, expensive, and increasingly well-recognized problem. Conservatively, 50% of published pre-clinical research is irreproducible, with an estimated annual cost of $28B in the United States alone. Lack of reproducibility typically results from cumulative errors or flaws in one or more of the following areas: reagents and reference materials, study design, laboratory protocols, and data analysis and reporting.

The Reproducibility2020 Challenge

GBSI challenges all bio-medical research community stakeholders to join with us to ensure that solutions are in place to improve reproducibility by the year 2020.

Strategies

1) Drive quality and ensure greater accountability through strengthened journal and funder policies.

2) Engage the research community in establishing community accepted standards and guidelines in specific scientific areas.

3) Create high quality online training and proficiency testing and make them widely accessible.

4) Enhance open access to data and methodologies.

Continued transparent, global, multi-stakeholder engagement is the way forward to better, more impactful science. GBSI calls on all stakeholders – individuals and organizations alike – to take action to improve reproducibility.

In its leadership role, GBSI will:

  • work with journals and funders to encourage policies that increase rigor, accountability and open access to data and methodologies,
  • lead the effort toward improving the validation of reagents—particularly cells and antibodies— and work with the research community to explore other scientific areas (e.g. stem cells and synthetic biology) where a greater emphasis on development of standards and best practices are needed to ensure quality and advance discovery, and
  • make high quality, accessible online training modules available to both emerging and experienced researchers who are eager to improve their proficiencies in new and evolving best practices.
  • report annually on the research community’s progress to date and priorities moving forward.